Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 28:4:8.
doi: 10.21037/tbcr-22-41. eCollection 2023.

Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer

Bruno Henrique Rala de Paula  1 , Susanne Crocamo  1 , Jose Bines  2
Affiliations

Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer

Bruno Henrique Rala de Paula et al. Transl Breast Cancer Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tbcr.amegroups.com/article/view/10.21037/tbcr-22-41/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Clinical trial approach consideration for (ER−PR+HER2−) breast cancer in clinical practice. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factors receptor; IHC, immunohistochemistry; CK, cytokeratin; TFF, trefoil factor; EGFR, endothelial growth factor receptor; pCR, pathological complete response; DFS, disease-free survival; OS, overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Kunc M, Biernat W, Senkus-Konefka E. Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact? Cancer Treat Rev 2018;67:78-87. 10.1016/j.ctrv.2018.05.005 - DOI - PubMed
    1. Itoh M, Iwamoto T, Matsuoka J, et al. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Res Treat 2014;143:403-9. 10.1007/s10549-013-2763-z - DOI - PubMed
    1. Sarrif AM, Durant JR. Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor. Cancer 1981;48:1215-20. 10.1002/1097-0142(19810901)48:5<1215::AID-CNCR2820480527>3.0.CO;2-3 - DOI - PubMed
    1. De Maeyer L, Van Limbergen E, De Nys K, et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 2008;26:335-6; author reply 336-8. 10.1200/JCO.2007.14.8411 - DOI - PubMed